{
  "ticker": "PTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969693",
  "id": "02969693",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250716",
  "time": "0908",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06lv40qk7dvscg.pdf",
  "summary": "- **Clinical Trial Update**: First U.S. site initiated for PTX-100 Phase 2a trial in Cutaneous T-Cell Lymphoma (CTCL) at VCU Massey Comprehensive Cancer Center.  \n- **Enrollment Status**: 4 patients already enrolled across 3 Australian sites; U.S. recruitment now open.  \n- **Regulatory Status**: PTX-100 holds FDA Orphan Drug and Fast Track Designations for T-Cell Lymphomas.  \n\nNo material capital markets or trading-specific information identified.",
  "usage": {
    "prompt_tokens": 2696,
    "completion_tokens": 108,
    "total_tokens": 2804,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-15T23:31:19.316324"
}